🏛️ Verified NIH Record • Updated 2026-06-08
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC (NCT05798663)
Randomized Phase II Trial of Neoadjuvant and Adjuvant Atezolizumab With or Without Tiragolumab in Conjunction With Chemoradiotherapy for Unresectable Stage III NSCLC
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Alliance Foundation Trials, LLC.
🩺 Plain-English Summary (8th-Grade Level)
This is a phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC.
Who can join: Review the eligibility criteria below.
Location: University of California San Diego Moores Cancer Center — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- University of California San Diego Moores Cancer Center — La Jolla, California
- Kaiser Permanente Oakland Medical Center — Oakland, California
- Kaiser Permanente Roseville Medical Center — Roseville, California
- Kaiser Permanente San Francisco Medical Center — San Francisco, California
- Kaiser Permanente Santa Clara Medical Center — Santa Clara, California
- Kaiser Permanente Vallejo Medical Center — Vallejo, California
- Rush University Medical Center — Chicago, Illinois
- Washington University Siteman Cancer Center — St Louis, Missouri
- Missouri Baptist Medical Center — St Louis, Missouri
- University of Nebraska Medical Center — Omaha, Nebraska
- New Hampshire Oncology - Hematology, PA — Manchester, New Hampshire
- Hematology Oncology Associates of Central New York, P.C. — East Syracuse, New York
- SUNY Upstate Medical University — Syracuse, New York
- Ohio State University — Columbus, Ohio
- University of Wisconsin — Madison, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in NSCLC
- Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy — Savannah, Georgia
- A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC — Daphne, Alabama
- A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care — Boston, Massachusetts
- Study of Oral MRT-2359 in Selected Cancer Patients — Scottsdale, Arizona
- Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations — Phoenix, Arizona
Explore by condition: All NSCLC clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.